2022 JUL 15 (NewsRx) — By a News Reporter-Staff News Editor at Information Technology Business Day by day — Recent research on Cancer is the topic of a report. In keeping with news reporting originating from Rennes, France, by NewsRx correspondents, research stated, “Published algorithms for identifying chronic kidney disease in healthcare claims databases have poor performance except in patients with renal substitute therapy. We propose and describe an algorithm to discover all stage chronic kidney disease in a French healthcare claims databases and assessed its performance through the use of data from the Renal Epidemiology and Information Network registry and the French Childhood Cancer Survivor Study cohort.”
Our news editors obtained a quote from the research from the University of Rennes, “A gaggle of experts met several times to define a listing of things and combos of things that may very well be related to chronic kidney disease. For the French Childhood Cancer Survivor Study cohort, information on confirmed chronic kidney disease cases extracted from medical records was considered the gold standard (KDIGO definition). Sensitivity, specificity, and positive and negative predictive value and kappa coefficients were estimated. The contribution of every component of the algorithm was assessed for 1 and a pair of years before the beginning of renal substitute therapy for confirmed end-stage kidney disease within the Renal Epidemiology and Information Network registry. The algorithm’s sensitivity was 78%, specificity 97.4%, negative predictive value 98.4% and positive predictive value 68.7% in French Childhood Cancer Survivor Study cohort and the kappa coefficient was 0.79 for agreement with the gold standard. The algorithm 93.6% and 55.1% of confirmed incident end-stage kidney disease cases from the Renal Epidemiology and Information Network registry when considering 1 yr and a pair of years, respectively, before renal substitute therapy start. The algorithm showed good performance amongst younger patients and people with end-stage kidney disease within the twol last years prior to renal substitute therapy.”
In keeping with the news editors, the research concluded: “Future research will address the power of the algorithm to detect early chronic kidney disease stages and to categorise the severity of chronic kidney disease.”
This research has been peer-reviewed.
For more information on this research see: An algorithm for identifying chronic kidney disease within the French national medical insurance claims database. Nephrologie & Therapeutique, 2022. Nephrologie & Therapeutique may be contacted at: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France. (Elsevier – www.elsevier.com; Nephrologie & Therapeutique – http://www.journals.elsevier.com/nephrologie-and-therapeutique/)
The news editors report that additional information could also be obtained by contacting Maxime Raffray, University of Rennes, French School of Public Health (EHESP), REPERES (Recherche en pharmaco-epidemiologie et recours aux soins)-EA 7449, 35000 Rennes, France. Additional authors for this research include Imene Mansouri, Mathilde Lassalle, Florent de Vathaire, Brice Fresneau, Chiraz Fayech, Helene Lazareth, Nadia Haddy, Sahar Bayat and Cecile Couchoud.
Publisher contact information for the journal Nephrologie & Therapeutique is: Elsevier Masson, Corp Off, 65 Camille Desmoulins CS50083 Issy-Les-Moulineaux, 92442 Paris, France.
(Our reports deliver fact-based news of research and discoveries from around the globe.)